|
| Press Releases |
|
 |
|
| Thursday, July 4, 2013 |
|
|
Nanobiotix Announces EUR 2.8 Million Grant from bpifrance to Accelerate Development of NBTXR3 in a Third New Indication |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today it has secured c.EUR 9 million in funding from bpifrance (formerly OSEO) of which EUR 2.8 million is directly attributable to the Company. more info >> |
|
| Wednesday, June 26, 2013 |
|
|
Nanobiotix Announces the Selection of its Second NanoXray Product, NBTX-IV and a Collaboration with the National Cancer Institute for Development |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the selection of a new product for development, NBTX-IV. more info >> |
|
| Thursday, June 13, 2013 |
|
|
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO) announces today that its lead compound NBTXR3 has received authorization from the French Medicine Agency, ANSM, to start a clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer), at the Institut Curie, Paris, France, a French leading cancer treatment center. more info >> |
|
| Monday, June 3, 2013 |
|
|
Nanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive Phase I interim results of its lead nanoparticle-based product, NBTXR3, in patients with Soft Tissue Sarcoma (STS). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
SAKENOVA: 28-Year-Old Master Brewer Pioneers AI-Driven Sake Revolution, Achieving 40% Cost Reduction While Winning International Gold Medals 
Dec 15, 2025 23:00 JST
|
|
|
GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes
Dec 15, 2025 21:09 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
Dec 15, 2025 21:00 HKT/SGT
|
|
|
NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport
Dec 15, 2025 19:41 JST
|
|
|
NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz
Dec 15, 2025 19:04 JST
|
|
|
Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares
Dec 15, 2025 16:59 HKT/SGT
|
|
|
Indonesia's KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge
Dec 15, 2025 13:00 HKT/SGT
|
|
|
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations
Dec 15, 2025 09:51 HKT/SGT
|
|
|
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership
Dec 15, 2025 8:30 JST
|
|
|
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Dec 12, 2025 23:15 JST
|
|
|
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Dec 12, 2025 14:35 HKT/SGT
|
|
|
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition
Dec 12, 2025 11:00 JST
|
|
|
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
Dec 11, 2025 20:00 HKT/SGT
|
|
|
Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing
Dec 11, 2025 18:09 HKT/SGT
|
|
|
Nasdaq Verafin Joins Global Anti-Scam Alliance
Dec 11, 2025 14:21 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
